We use essential cookies to make our site work. With your consent, we may also use non-essential cookies to improve user experience and analyze website traffic. By clicking “Accept,” you agree to our website's cookie use as described in our Cookie Policy. You can change your cookie settings at any time by clicking “Preferences.”
About

Market Analysis

65%
F&G: 41
EARLY RECOVERYYield: 0.65%
Today’s market action is being driven primarily by relief around a reported US–Iran agreement to reopen the Strait of Hormuz, lifting major US indices and reinforcing a risk-on tone across equities. Tech and other growth segments are leading the charge, while select media and energy names show that stock-specific risks remain very much in play. With volatility recently easing and sentiment improving, the opportunity set for investors is expanding, but so is the need for careful selection, diversification, and disciplined risk management. Position portfolios to participate in upside driven by better geopolitical visibility, while staying prepared for the next bout of uncertainty.

Market Pulse

65% advancingEARLY RECOVERY phase
licensing 3.18%, advertising 2.79%

Fear & Greed

41fear

Outlook

Global Economic Rebound 30%Central Bank Pivot 25%Stagflation 20%

Sectors

Technology 2.06%, Health Care 1.74%Energy -1.85%, Real Estate -0.24%

Bonds

3M:3.80%10Y:4.45%
Slope:0.65%(normal)

News

The US government's Anthropic models ban was never about an AI jailbreak
The US government's Anthropic models ban was never about an AI jailbreak
📊Thesis Ideas Based on Market Conditions
📈 AI Infrastructure Buildout Accelerates as Data Center Capex Hits Record $350B in 2026
📉 Dollar Weakness Fuels EM Equity Surge as Fed Rate Cuts Begin Amid Global Policy Divergence
🔄 Sector Rotation Intensifies as Fed Rate Cut Cycle Begins, Cyclicals Outperform After 3-Year Underperformance
🌍 Defense Spending Hits Record $950B as NATO Allies Boost Military Capex Amid Escalating Middle East Tensions
📈 Enterprise Software Margins Squeeze as Corporations Redirect 30% of IT Budget to AI Infrastructure Capex
📈 AI Infrastructure Buildout Accelerates as Data Center Capex Hits Record $350B in 2026
📉 Dollar Weakness Fuels EM Equity Surge as Fed Rate Cuts Begin Amid Global Policy Divergence
🔄 Sector Rotation Intensifies as Fed Rate Cut Cycle Begins, Cyclicals Outperform After 3-Year Underperformance
🌍 Defense Spending Hits Record $950B as NATO Allies Boost Military Capex Amid Escalating Middle East Tensions
📈 Enterprise Software Margins Squeeze as Corporations Redirect 30% of IT Budget to AI Infrastructure Capex
Date
Company
Employee Outlook
Market Cap
Growth
Short %
Signals
Analysts Rating
Industry
Economic Events:
Sentiment:10%
Companies developing GLP-1 and metabolic regulation drugs-0.4%2↑ / 5↓     
Jul 27
42 days
Astrazeneca PLC logo
Astrazeneca PLC (AZN)
astrazeneca.com
0.79 -2%$274.98B12.50%0.11%1.4 Strong BuyDrug Manufacturers - General
Jul 29
44 days
Pfizer logo
Pfizer (PFE)
pfizer.com
0.50 -3%$149.13B-5.90%2.29%
2.4 BuyDrug Manufacturers - General
Jul 30
45 days
Sanofi logo
Sanofi (SNY)
sanofi.com
0.64 -1%$104.85B-7.00%0.36%
2.1 BuyDrug Manufacturers - General
Aug 4
50 days
Amgen Inc. logo
Amgen Inc. (AMGN)
amgen.com
0.70 +0%$192.44B8.60%2.67%2.5 BuyDrug Manufacturers - General
Aug 5
51 days
Eli Lilly and Company logo
Eli Lilly and Company (LLY)
lilly.com
0.81 -1%$1.00T53.90%0.82%1.7 BuyDrug Manufacturers - General
Aug 5
51 days
Novo logo
Novo (NVO)
novonordisk.com
0.42 -2%$194.48B5.10%0.96%
2.4 BuyBiotechnology
Aug 6
52 days
Viatris Inc. logo
Viatris Inc. (VTRS)
viatris.com
0.59 -3%$19.06B8.10%3.28%
2.2 BuyDrug Manufacturers - Specialty & Generic